AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

American Association of Orthopaedic Surgeons (AAOS) President Daniel K. Guy, MD, FAAOS, issued the following statement in response to the newly released Calendar Year (CY) 2022 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Most notably, the Centers for Medicare & Medicaid Services (CMS) is proposing to halt the elimination of the Inpatient Only (IPO) list and place the 298 services that were previously removed back onto the list beginning in CY 2022.

“AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only (IPO). We continue to support the removal of procedures which have been proven to be done safely in the outpatient setting; however, there is much work left to be done to clarify what these changes mean in order to avoid widespread confusion and unintended consequences for patient care. Orthopaedic surgeons know firsthand from their experience with total knee arthroplasty removal in 2018, total hip arthroplasty in 2020, and then the removal of all musculoskeletal procedures in 2021 how challenging such a dramatic shift can be to safe and timely musculoskeletal care.

“Now as the agency reassess how it will evaluate future procedures for removal and the longer-term plan for the IPO, it should place more emphasis on physicians leading those decisions and prioritize the value of patient choice. CMS must also be careful to avoid creating new regulatory barriers to determining the appropriate setting of care as an overcorrection to the policy reversal—especially now after the country has benefited from such flexibilities and individualized medicine during the COVID-19 pandemic.

“Transparency around these changes and input from the medical community are critical to the successful implementation of the rule. We look forward to commenting on the proposal in greater detail and offering our formal comments later this year on behalf of the musculoskeletal community.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution